CoChat

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.

Bevacizumab

Open access

Abstract

Learning Objectives: After completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to predict degrees of patient response. CME This article is available for continuing medical education credit at CME.TheOncologist.com.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2009-0317

Cites

40 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 6

  1. U. S. Food and Drug Administration, Center for Drug Evaluation and Research. Final Labeling Text, BL125085 Supplement, 2008
  2. The European Medicines Agency, European Public Assessment Report. Avastin Product Information. Avastin-H-C-582-II-23, August 2008
  3. Pegram, 2006, Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer [abstract S28], Breast Cancer Res Treat, 100, S28
  4. Gaudreault, 2001, Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC), Clin Pharmacol Ther, 69, 25
  5. U. S. Food and Drug Administration, Center for Drug Evaluation and Research. 2008 Safety Alerts for Human Medical Products. Dear Healthcare Professional Letter - Genentech
  6. National Institute for Health and Clinical Excellence, TA118 Colorectal Cancer (Metastatic) – Bevacizumab & Cetuximab: Guidance; January 2007

Cited by

See all 293

Metadata

Authors
Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M.
Affiliations
Utrecht University (NL)
Corresponding author
Schellens, Jan H. M.
Venue
The Oncologist
Published
2010-08-01
Volume
15
Issue
8
Pages
819-825
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W4234401042
Cited by
291
References
41
Citations by year
2026: 19 · 2025: 35 · 2024: 45 · 2023: 51 · 2022: 44 · 2021: 38 · 2020: 21 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 5 · 2014: 1 · 2013: 6 · 2012: 4
FWCI
0.48
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
bevacizumab, anti-VEGF therapy, cancer therapy, combination chemotherapy, mechanism of action, treatment response prediction
MeSH terms
Bevacizumab, Animals, Antibodies, Monoclonal, Humans, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab. https://app.cochat.ai/papers/10.1634/theoncologist.2009-0317
The paper
Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M. (2010). Bevacizumab. The Oncologist. https://doi.org/10.1634/theoncologist.2009-0317

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.